Another HDL Therapy Crashes and Burns

ACC Conference Reporter

ACC.17 | WASHINGTON, DC — Once again, an HDL-inspired therapy has failed when put to the test in a clinical trial. Although there are still ongoing trials with other HDL-related therapies, most experts now feel that it is time for the field to turn its attention elsewhere and give up on HDL as a worthwhile model for new therapies and trials. Read More >>>

Keywords: ACC17, ACC Annual Scientific Session

< Back to Listings